Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases]

Details

Ressource 1Request a copy Under embargo until 26/11/2022.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_7FA860CBBECC
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases]
Journal
Revue medicale suisse
Author(s)
Lu H., Hullin R., Yerly P., Meyer P., Kosinski C., Daux A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
26/05/2021
Peer-reviewed
Oui
Volume
17
Number
740
Pages
1034-1038
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which offer cardiovascular (CV) and renal benefits. They are currently indicated as first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV disease, high CV risk, renal disease, or heart failure with reduced ejection fraction (HFrEF). Two randomized clinical trials have shown the benefits of dapagliflozin and empagliflozin in patients with HFrEF, regardless of the presence of T2DM. Despite an overall favorable safety profile, attention has to be paid to adverse events, such as an increased risk of euglycemic diabetic ketoacidosis and genital mycotic infections. We present an up-to-date narrative literature review of the physiological mechanisms of action, current indications, and side effects of SGLT2 inhibitors.
Keywords
Benzhydryl Compounds/adverse effects, Cardiovascular Diseases/chemically induced, Diabetes Mellitus, Type 2/drug therapy, Heart Failure, Humans, Hypoglycemic Agents/adverse effects, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, Stroke Volume
Pubmed
Create date
15/06/2021 9:57
Last modification date
18/08/2022 7:11
Usage data